IL17A and psoriasis vulgaris: Secukinumab (SECU) is a promising fully human anti-IL-17 monoclonal antibody that selectively neutralizes IL-17A, approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.